Our top pick for
Building a portfolio
Orchard Therapeutics plc is a biotechnology business based in the US. Orchard Therapeutics shares (ORTX) are listed on the NASDAQ and all prices are listed in US Dollars. Orchard Therapeutics employs 224 staff and has a trailing 12-month revenue of around USD$2.6 million.
|52-week range||USD$3.76 - USD$12.377|
|50-day moving average||USD$7.3976|
|200-day moving average||USD$5.7964|
|Wall St. target price||USD$15.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.273|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$2.6 million|
|Gross profit TTM||USD$1.7 million|
|Return on assets TTM||-26.5%|
|Return on equity TTM||-63.64%|
|Market capitalisation||USD$784.2 million|
TTM: trailing 12 months
There are currently 4.8 million Orchard Therapeutics shares held short by investors – that's known as Orchard Therapeutics's "short interest". This figure is 10.2% down from 5.3 million last month.
There are a few different ways that this level of interest in shorting Orchard Therapeutics shares can be evaluated.
Orchard Therapeutics's "short interest ratio" (SIR) is the quantity of Orchard Therapeutics shares currently shorted divided by the average quantity of Orchard Therapeutics shares traded daily (recently around 1.1 million). Orchard Therapeutics's SIR currently stands at 4.52. In other words for every 100,000 Orchard Therapeutics shares traded daily on the market, roughly 4520 shares are currently held short.
However Orchard Therapeutics's short interest can also be evaluated against the total number of Orchard Therapeutics shares, or, against the total number of tradable Orchard Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orchard Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Orchard Therapeutics shares in existence, roughly 40 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Orchard Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orchard Therapeutics.
Find out more about how you can short Orchard Therapeutics stock.
We're not expecting Orchard Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Orchard Therapeutics's shares have ranged in value from as little as $3.76 up to $12.377. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orchard Therapeutics's is 1.2305. This would suggest that Orchard Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.